Fact or Fallacy: Acute Pain Management in Patients Receiving Buprenorphine Products
by Johanna Van Epps, PharmD, Jeffrey Fish, PharmD, FCCM, BCCCP
Question:
How should acute pain be managed in patients receiving buprenorphine (BUP) products?
Opioid use disorder (OUD) pattern of opioid use leading to clinically significant impairment or distress. OUD is a serious public health problem with three million people in the United States and 16 million people worldwide suffering with the diagnosis. Medications for opioid use disorder (MOUD), previously called “medication assisted treatment (MAT),” describes an evidence-based approach that utilizes medications, including BUP, to treat individuals with OUD. When patients with OUD are hospitalized, it’s crucial that both MOUD and pain management therapies are optimized, as patients with substance use disorders (SUD) have high rates of hospitalization, readmission, and increased risk of SUD recurrence following hospital discharge.
Download PDF
2025 July/August Table of Contents
Question:
How should acute pain be managed in patients receiving buprenorphine (BUP) products?
Opioid use disorder (OUD) pattern of opioid use leading to clinically significant impairment or distress. OUD is a serious public health problem with three million people in the United States and 16 million people worldwide suffering with the diagnosis. Medications for opioid use disorder (MOUD), previously called “medication assisted treatment (MAT),” describes an evidence-based approach that utilizes medications, including BUP, to treat individuals with OUD. When patients with OUD are hospitalized, it’s crucial that both MOUD and pain management therapies are optimized, as patients with substance use disorders (SUD) have high rates of hospitalization, readmission, and increased risk of SUD recurrence following hospital discharge.
Download PDF
2025 July/August Table of Contents